Though there are four histone deacetylase (HDAC) inhibitors that are FDA approved to treat some forms of lymphoma, there’s less evidence for their efficacy in solid tumors. Now, new findings in mice ...

Simultaneous inhibition of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) is considered a good strategy in cancer treatment, although current PI3K/HDAC dual inhibitors have ...

Most pancreatic tumors are surrounded by a thick, nearly impenetrable wall of fibrosis— scar tissue—that makes it hard for drugs to access and destroy the cancer cells. Researchers at the Salk ...

Expanding on this foundation of knowledge, researchers in the Zhou Lab and the Cheung Lab at Mount Sinai plan to concentrate on refining class IIa HDAC inhibitors with better efficacies for treating ...

Pancreatic cancer is one of the deadliest cancers - only about one in eight patients survives five years after diagnosis. Those dismal statistics are in part due to the thick, nearly impenetrable wall ...

Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone (CMOP) for patients with treatment-naïve peripheral T-cell lymphomas (PTCLs): Extended follow-up ...

GOTHENBURG, Sweden, Jan. 14, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare ...

Epigenetics is the study of changes in organisms caused by modifying gene expression - by alcohol, for example - rather than alteration of the genetic code itself. Recent evidence suggests that ...

The Global Peripheral T-Cell Lymphoma Market is poised for significant growth, driven by a rising incidence of lymphoma and adoption of novel targeted therapies and immunotherapies. Peripheral T-cell ...

A drug with a past life as a potential anti-cancer agent might someday have a new job as "the pill" for men, new data in mice suggest. In a journal article published Feb. 20 in Proceedings of the ...